2024
Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinomaSmall Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study
Bakaloudi D, Koehne E, Diamantopoulos L, Holt S, Sekar R, Ghali F, Vakar-Lopez F, Nyame Y, Psutka S, Gore J, de la Calle C, Lin D, Schade G, Liao J, Hsieh A, Yezefski T, Hawley J, Yu E, Montgomery R, Grivas P, Wright J. Small Cell Bladder Cancer: Treatment Patterns for Local Disease and Associated Outcomes. A Retrospective Cohort Study. Clinical Genitourinary Cancer 2024, 22: 102208. PMID: 39265260, DOI: 10.1016/j.clgc.2024.102208.Peer-Reviewed Original ResearchSmall cell bladder cancerConcurrent chemoradiotherapyNeoadjuvant chemotherapySEER-Medicare databaseMedian OSLocoregional therapySEER-MedicareBladder cancerHistological subtypesOverall survivalInstitutional databaseCompare outcomesOptimal locoregional therapyAggressive histologic subtypeNon-metastatic stageNon-metastatic diseaseSEER-Medicare datasetMultivariate Cox analysisFollow-up/deathLocalized diseaseCox analysisCystectomyTreatment patternsTreatment responseMultivariate analysisPatterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older
Ghali F, Holt S, Koehne E, Chen J, Weg E, Liao J, Zeng J, Grivas P, Hawley J, Hsieh A, Montgomery R, Wright J. Patterns of chemotherapy use with primary radiotherapy for localized bladder cancer in patients 65 or older. Frontiers In Oncology 2024, 14: 1341655. PMID: 38812783, PMCID: PMC11133586, DOI: 10.3389/fonc.2024.1341655.Peer-Reviewed Original ResearchMuscle invasive bladder cancerPatterns of chemotherapy useRadiation therapyReceipt of chemotherapyChemotherapy useMultivariate logistic regressionConcurrent chemotherapyOverall survivalBladder cancerFactors associated with receipt of chemotherapyMaximum transurethral resection of bladder tumorNational Cancer Institute comorbidity indexTransurethral resection of bladder tumorAlternative to radical cystectomyAssociated with superior OSReceipt of concurrent chemotherapyResection of bladder tumorCurative-intent RTLow dose gemcitabineUtilization of chemotherapyLocalized bladder cancerInvasive bladder cancerFactors associated with receiptYear of diagnosisSuperior disease controlAdjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer
Koehne E, Bakaloudi D, Ghali F, Nyame Y, Schade G, Grivas P, Yezefski T, Hawley J, Yu E, Hsieh A, Montgomery R, Psutka S, Gore J, Wright J. Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer. Clinical Genitourinary Cancer 2024, 22: 102100. PMID: 38763862, DOI: 10.1016/j.clgc.2024.102100.Peer-Reviewed Original ResearchNational Cancer DatabaseAdjuvant chemotherapyReceipt of ACRadical cystectomyBladder cancerOverall survivalAssociated with significantly longer OSAssociated with OS benefitNon-metastatic bladder cancerMultivariate Cox regression analysisPrevalence of adenocarcinomaSquamous cell histologyMultivariate Cox regressionCox regression analysisMultivariate logistic regressionAssociated with lower oddsAssociated with greater oddsNeuroendocrine histologyLonger OSOS benefitCell histologyHistological subtypesCancer DatabaseClinicopathological featuresCox regression
2022
Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry
Meagher MF, Mir MC, Autorino R, Minervini A, Kriegmair M, Maurer T, Porpiglia F, Van Bruwaene S, Linares E, Hevia V, Musquera M, Roussel E, Pavan N, Antonelli A, Zhang S, Ghali F, Patel D, Javier-Desloges J, Bradshaw A, Rubio J, Guruli G, Tracey A, Campi R, Albersen M, Furlan M, McKay RR, Derweesh IH. Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry. Clinical Genitourinary Cancer 2022, 20: 326-333. PMID: 35585014, DOI: 10.1016/j.clgc.2022.03.013.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaCancer-specific mortalityKaplan-Meier analysisHigh-risk groupImpact of metastasectomyRenal cell carcinomaCell carcinomaMultimodal management strategyPotential prognostic variablesHigh-risk patientsMulticenter retrospective analysisCox regression analysisIntermediate-risk subgroupsMedian OSMRCC patientsCause mortalitySurgical metastasectomyOverall survivalPrimary outcomeSecondary outcomesSpecific survivalCox regressionCancer-SpecificTreatment paradigmMetastasectomyDoes presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis.
Saidian A, Walia A, Patil D, Saito K, Patel D, Nguyen M, Chakoumakos M, Ghali F, Narasimhan R, Perry J, Meagher M, Yasuda Y, Fujii Y, Master V. Does presence of diabetes mellitus impact patient oncological outcomes in renal cell carcinoma: A multicenter analysis. Journal Of Clinical Oncology 2022, 40: 325-325. DOI: 10.1200/jco.2022.40.6_suppl.325.Peer-Reviewed Original ResearchRenal cell carcinomaProgression-free survivalKaplan-Meier analysisCancer-specific survivalIndependent risk factorMultivariable analysisDiabetes mellitusRisk factorsOverall survivalCell carcinomaStage ICox regression multivariable analysisImpact of DMPatients' oncological outcomesNon-diabetic patientsRegression multivariable analysisOncologic effectCause mortalityOncological outcomesDiabetic patientsMulticenter analysisMeier analysisMale sexRCC patientsStage subgroupsDisparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
Meagher M, Patil D, Saito K, Javier-Desloges J, Bradshaw A, Patel S, Cotta B, Yasuda Y, Eldefrawy A, Ghali F, Nasseri R, Wan F, Fujii Y, Master V, Derweesh I. Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC). Urology 2022, 163: 164-176. PMID: 34995562, DOI: 10.1016/j.urology.2021.12.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCancer-specific mortalityCancer-specific survivalKaplan-Meier analysisCause mortalityOverall survivalMultivariable analysisSurvival outcomesCell carcinomaStage IIIStage IFive-year cancer-specific survivalAfrican AmericansNon-African American patientsRenal cancer databasePapillary renal cell carcinomaOverall survival outcomesAfrican American raceStage III/IV RCCHigher stageIndolent histologiesSecondary outcomesPrimary outcomeRadical nephrectomyPositive margins
2021
Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients
Javier-DesLoges JF, Meagher MF, Walia A, Nguyen MV, Perry JM, Narasimhan RS, Hakimi K, Soliman S, Yuan J, Chakoumakos MA, Ghali F, Patel DN, Wan F, Murphy JD, Derweesh IH. Evaluation of the association of health care system access with kidney cancer surgical outcomes for hispanic and non-hispanic white patients. Urologic Oncology Seminars And Original Investigations 2021, 39: 837.e1-837.e7. PMID: 34580026, DOI: 10.1016/j.urolonc.2021.08.021.Peer-Reviewed Original ResearchConceptsNon-Hispanic white patientsCancer-specific survivalRenal cell carcinomaMedically Underserved AreasCause mortalityWhite patientsHealth care system accessSpecific survivalNon-Hispanic whitesLocalized Renal Cell CarcinomaTertiary referral centerCause mortality riskKaplan-Meier analysisLog-rank testCancer surgical outcomesOverall survivalReferral centerSecondary outcomesPrimary outcomeHispanic patientsMeier analysisCox regressionSurgical outcomesCell carcinomaRisk factorsMP45-12 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT ON INSURANCE STATUS, CANCER STAGE, AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA
Javier-DesLoges J, Hakimi K, Yuan J, Soliman S, Meagher M, Ghali F, Nawalade V, Patel D, Murphy J, Jolla, CA L, Kim S, Derweesh I. MP45-12 THE ASSOCIATION BETWEEN THE AFFORDABLE CARE ACT ON INSURANCE STATUS, CANCER STAGE, AND OVERALL SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA. Journal Of Urology 2021, 206: e807-e808. DOI: 10.1097/ju.0000000000002066.12.Peer-Reviewed Original ResearchThe association between the Affordable Care Act on insurance status, cancer stage, and overall survival in patients with renal cell carcinoma.
Javier-Desloges J, Yuan J, Soliman S, Hakimi K, Meagher M, Ghali F, Hsiang W, Patel D, Murphy J, Kim S, Derweesh I. The association between the Affordable Care Act on insurance status, cancer stage, and overall survival in patients with renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 281-281. DOI: 10.1200/jco.2021.39.6_suppl.281.Peer-Reviewed Original ResearchRenal cell carcinomaMiddle-income patientsNon-expansion statesAffordable Care ActAbsolute percentage changeIncome patientsInsurance statusExpansion statesCox regression multivariable analysisNational Cancer DatabaseRegression multivariable analysisHigh-income patientsLow-income patientsInsurance coverage statusImplementation of ACALow incomeCause mortalityPatients 40Overall survivalStage diseaseAdvanced cancerMultivariable analysisCancer groupStage migrationCell carcinoma
2020
Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy
Ghali F, Daly W, Hansen M, Hayn M, Sammon J, Beaule L, Sarkar R, Murphy J, Kader A, Derweesh I, Rose B, Ryan S. Pathologic nodal downstaging in men with clinically involved lymph nodes undergoing radical prostatectomy: Implications for definitive locoregional therapy. Urologic Oncology Seminars And Original Investigations 2020, 39: 130.e1-130.e7. PMID: 33121914, DOI: 10.1016/j.urolonc.2020.08.035.Peer-Reviewed Original ResearchConceptsNodal statusRadical prostatectomyOverall survivalDiscordant stagingDiscordant statusSimilar OSLymph nodesClinical positive lymph nodesNational Cancer Data BaseClinical nodal stagingDefinitive locoregional therapyPathologic nodal statusUnderwent radical prostatectomyPositive lymph nodesPositive nodal statusLow Gleason scoreNegative node statusDifficult clinical scenariosKaplan-Meier estimationCharlson indexClinical nodalCM1 diseaseCT1-3Noncurative therapyPathologic nodalImpact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database
Ryan S, Patel D, Ghali F, Patel S, Sarkar R, Yim K, Eldefrawy A, Cotta B, Bradshaw A, Meagher M, Hamilton Z, Murphy J, Derweesh I. Impact of positive surgical margins on survival after partial nephrectomy in localized kidney cancer: analysis of the National Cancer Database. Minerva Urologica E Nefrologica 2020, 73: 233-244. PMID: 32748614, DOI: 10.23736/s2724-6051.20.03728-5.Peer-Reviewed Original ResearchConceptsPositive surgical marginsKaplan-Meier analysisRenal cell carcinomaNational Cancer DatabaseOverall survivalPartial nephrectomyMultivariable analysisSurgical marginsPathological stageCancer DatabaseCox regression multivariable analysisN0M0 renal cell carcinomaUS National Cancer DatabaseImpact of PSMRegression multivariable analysisPT3a diseaseCause mortalityMargin statusNegative marginsResection strategyCell carcinomaAggressive surveillanceRetrospective analysisKidney cancerPatients846 Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry
Meagher M, Mir M, Rubio J, Campi R, Minervini A, Kriegmair M, Heck M, Van Bruwaene S, Linares E, Hevia V, Musquera M, D’anna M, Ghali F, Patel D, Bradshaw A, Autorino R, Guruli G, Rousel E, Albertsen M, Pavan N, Claps F, Antonelli A, Palumbo C, Marchioni M, Derweesh I. 846 Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry. European Urology Open Science 2020, 19: e1285-e1286. DOI: 10.1016/s2666-1683(20)33444-3.Peer-Reviewed Original ResearchOncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis
Patel S, Uzzo R, Larcher A, Peyronnet B, Lane B, Pruthi D, Reddy M, Capitanio U, Joshi S, Noyes S, Eldefrawy A, Ghali F, Meagher M, Hamilton Z, Yim K, Nasseri R, Bradshaw A, Dey S, Kirmiz S, Wan F, Liss M, Bensalah K, Montorsi F, Derweesh I. Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis. Clinical Genitourinary Cancer 2020, 18: e723-e729. PMID: 32600941, DOI: 10.1016/j.clgc.2020.05.002.Peer-Reviewed Original ResearchConceptsKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaRecurrence-free survivalRadical nephrectomyPartial nephrectomyOverall survivalMultivariable analysisCell carcinomaFunctional outcomeDe novo eGFRGlomular filtration rateClinical T stageMulticenter retrospective analysisRisk of recurrenceMulti-institutional analysisPT3a upstagingOncologic outcomesSecondary outcomesPrimary outcomeIndependent predictorsSurvival outcomesT stagePositive marginsPredictive factorsImpact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study.
Dutt R, Meagher M, Patil D, Saito K, Patel D, Ghali F, Keiner C, Miller N, Bradshaw A, Wan F, Yasuda Y, Fujii Y, Master V, Derweesh I. Impact of diabetes mellitus on functional and survival outcomes in renal cell carcinoma: An international multicenter study. Journal Of Clinical Oncology 2020, 38: 666-666. DOI: 10.1200/jco.2020.38.6_suppl.666.Peer-Reviewed Original ResearchRenal cell carcinomaIndependent risk factorChronic kidney diseaseKaplan-Meier analysisRadical nephrectomyMultivariable analysisPartial nephrectomyRisk factorsPresence of DMFunctional declineDM statusOverall survivalKidney functionRCC patientsTumor sizeCell carcinomaRenal functional declineAfrican American raceInternational multicenter studyEffects of DMNDM patientsRN patientsCause mortalityWorse OSDiabetes mellitusDoes delay in time to surgery impact outcome in renal cell carcinoma: Analysis based on tumor size utilizing the National Cancer Database.
Patel D, Ghali F, Meagher M, Bradshaw A, Patel S, Murphy J, Derweesh I. Does delay in time to surgery impact outcome in renal cell carcinoma: Analysis based on tumor size utilizing the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 664-664. DOI: 10.1200/jco.2020.38.6_suppl.664.Peer-Reviewed Original ResearchMultivariable Cox proportional hazardsNational Cancer DatabaseRenal cell carcinomaKaplan-Meier analysisYears of ageTumor sizeSurgery delayWorse OSOverall survivalHealthy patientsCell carcinomaCancer DatabaseLocalized Renal Cell CarcinomaNon-private insuranceTumor size 2Charlson comorbidity scoreCox proportional hazardsComorbidity scoreSurgical treatmentSurvival impactMedian timeEntire cohortFourth quartileBlack raceActive surveillanceCharacterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer.
Ghali F, Patel D, Jamieson C, Parsons J, McKay R. Characterization of Wnt signaling pathway (WSP) aberrations in advanced prostate cancer. Journal Of Clinical Oncology 2020, 38: 203-203. DOI: 10.1200/jco.2020.38.6_suppl.203.Peer-Reviewed Original ResearchProstate cancerOverall survivalActivating mutationsDe novo metastatic diseaseAdvanced prostate cancerSomatic activating mutationsEligible patientsAdvanced diseaseGleason 8Visceral metastasesClinical characteristicsMetastatic diseaseOverall cohortMedian ageMedian timePCa patientsDisease characteristicsOutcome parametersCRPC developmentBiomarker statusDisease progressionMultiple malignanciesTreatment strategiesClinical significanceBRCA1/2 alterationsDoes pathologic upstaging to PT3A portend a worsened prognosis when compared to non-upstaged PT3A renal cell carcinoma: Analysis of the National Cancer Database.
Patel D, Ghali F, Meagher M, Bradshaw A, Patel S, Keiner C, Miller N, Dutt R, Murphy J, Derweesh I. Does pathologic upstaging to PT3A portend a worsened prognosis when compared to non-upstaged PT3A renal cell carcinoma: Analysis of the National Cancer Database. Journal Of Clinical Oncology 2020, 38: 624-624. DOI: 10.1200/jco.2020.38.6_suppl.624.Peer-Reviewed Original ResearchPT3a renal cell carcinomaRenal cell carcinomaNational Cancer DatabasePartial nephrectomyClinical stageOverall survivalPT3a tumorsCell carcinomaPathological upstagingUpstaged tumorsCancer DatabaseT3a renal cell carcinomaMultivariable Cox proportional hazardsKaplan-Meier survival analysisPre-treatment detectionRisk stratification protocolCharlson Comorbidity IndexImproved overall survivalFinal pathological analysisAJCC staging systemKaplan-Meier analysisSmaller tumor sizeLower clinical stagePositive margin statusCox proportional hazardsThe impact of metastasis location on overall survival among patients with renal cell carcinoma.
Patel D, Ghali F, Meagher M, Meagher M, Bradshaw A, Patel S, Keiner C, Miller N, Dutt R, Murphy J, Derweesh I. The impact of metastasis location on overall survival among patients with renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 621-621. DOI: 10.1200/jco.2020.38.6_suppl.621.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaRenal cell carcinomaNational Cancer DatabaseLiver/lung metastasisOverall survivalBone metastasesLung metastasesCell carcinomaInstitutional databaseUnivariate analysisMetastasis locationWorse OSSite metastasisDisease locationMultivariable Cox proportional hazardsKaplan-Meier survival analysisCurrent staging guidelinesLung/liver metastasisLog-rank testingWorse overall survivalHeterogeneity of patientsCox proportional hazardsLung/liverLiver metastasesMetastatic diseaseMulticenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma.
Bradshaw A, Ghali F, Miller N, Keiner C, Dutt R, Meagher M, Yim K, Patel D, Uzzo R, Lane B, Capitanio U, Derweesh I. Multicenter comparison of outcomes for clinical and pathologic T3a renal cell carcinoma. Journal Of Clinical Oncology 2020, 38: 758-758. DOI: 10.1200/jco.2020.38.6_suppl.758.Peer-Reviewed Original ResearchRecurrence-free survivalCancer-specific survivalKaplan-Meier analysisRenal cell carcinomaPT3a renal cell carcinomaOverall survivalMultivariable analysisSecondary outcomesPrimary outcomeCell carcinomaT3a renal cell carcinomaPathologic tumor sizePoor oncologic outcomesRegression multivariable analysisClear cell histologyLog-rank testPre-operative imagingPositive margin rateHigh recurrence rateAdvanced diseaseCell histologyOncologic outcomesVenous involvementMulticenter analysisOS rates